secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001815776-25-000054
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ reports Q2 net loss $14.9M; LNZ100 PDUFA on track for Aug 8, 2025
----------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $209.6M as of June 30, 2025; >$205M expected by PDUFA date.
- Net loss $14.9M ($0.53 per share) for Q2 2025 vs $10.3M ($0.40) in Q2 2024.
- NDA for LNZ100 (aceclidine for presbyopia) under FDA review; PDUFA target Aug 8, 2025; no advisory committee.
- Commercial team of 88 sales force hired and trained; launch ready upon FDA approval.
- Executed multiple international license deals totaling >$195M potential milestones plus double-digit royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/0001815776-25-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/lenz-20250730.htm
  HTML page:      https://secwatch.observer/filing/0001815776-25-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer